Non-Small Cell Lung Cancer (NSCLC): A Deep Dive into Recent Advances for Personalized Treatment

 

 

 

 


ACKNOWLEDGEMENT

This activity is supported by educational grants from Merck, BMS, Boehringer Ingelheim and Novartis.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ Health Education, LLC. Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Internet Activity
Session One: Tuesday, May 19, 2015 from 12:00 PM EST – 1:00 PM EST
Session Two: Wednesday, August 12, 2015 from 12:00 PM EST – 1:00PM EST

Enduring Material
The enduring material will be available from May 19, 2015 to February 12, 2016.


LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Apply guideline recommendation for genetic testing when evaluating a patient with advanced NSCLC
Summarize best practices for patient selection and tissue handling during testing for genetic mutations in NSCLC
Summarize current treatment options, their key therapeutic targets, adverse effects and their limitations for treatment of advanced NSCLC
Evaluate safety and efficacy of emerging novel treatment options and their potential impact for improving outcomes for patients with advanced NSCLC

INTENDED AUDIENCE
This activity is intended for medical and surgical oncologists, radiation oncologists, pulmonologists, oncology nurses and other members of the multidisciplinary healthcare team responsible for the diagnosis and management of patients with non-small cell lung cancers.

ESTIMATED TIME TO COMPLETE
The activity consists of two sessions, each of which should take approximately 1.0 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post- test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Panos Fidias, MD Speakers Bureau: Genentech, Bristol Myers Squibb, Boehringer Ingelheim
Advisory Board: Boehringer Ingelheim
Mark Socinski, MD Research Funding: Pfizer, Celgene, Synta, Clovis, GSK, BMS, BIND, Genentech
Speaker's Bureau: Celgene, Genentech
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University have no disclosures to report relative to this activity.
Amit K. Verma, MB, BS Has nothing to disclose relevant to this activity.
PlatformQ Health, Inc  
Ann Roc, Medical Director Has nothing to disclose relevant to this activity.
Randi O'Hara, Senior Program Manager Has nothing to disclose relevant to this activity.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

The Evolving Landscape of Advanced Melanoma Treatment

 

 

 

 


ACKNOWLEDGEMENT

This activity is supported by educational grants from Merck & Co., Inc. and Genentech, Inc.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ Health Education, LLC. Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Tuesday, September 22, 2015 from 9:00AM EST to 11:00AM EST.
Enduring Material
The enduring material will be available from September 22, 2015 to March 22, 2016.


LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Describe the pathophysiology of melanoma
Outline mechanisms of response and resistance associated with existing agent classes
Review efficacy and safety data from recent clinical trials investigating emerging and potential therapeutic combinations
Describe the range of immune response-related and dermatologic adverse events associated with existing and emerging immunomodulatory and targeted therapies for patients with metastatic melanoma
Identify strategies for predicting response to therapy in patients with melanoma being treated with single agent or combination BRAF
Select appropriate interventions to manage side effects in patients with melanoma being treated with single agent or combination immune-based/targeted therapy


INTENDED AUDIENCE

Medical oncologists, dermatologists, surgical oncologists, pathologists, general surgeons, oncology nurse practitioners/physician assistants, oncology nurses, and other clinicians involved in the diagnosis and treatment of melanoma are the target audience for this planned activity.

ESTIMATED TIME TO COMPLETE
The activity consists of two sessions, each of which should take approximately 1.0 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post- test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Jeffrey Weber, MD, PhD Consultant: Astra-Zeneca, Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Merck, Novartis
Sanjiv Agarwala, MD Has nothing to disclose.
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University have no disclosures to report relative to this activity.
Amit K. Verma, MB, BS Has nothing to disclose relevant to this activity.
PlatformQ Health, Inc  
Deborah Sharkey, Senior Program Manager Has nothing to disclose relevant to this activity.
Anne Roc, Medical Director Has nothing to disclose relevant to this activity.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Nursing Perspectives for Optimizing Outcomes in Hemophilia Treatment

 

 

 

 

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC


ACKNOWLEDGEMENT

This activity is supported by an independent educational grant from Biogen.

TUITION
Complimentary


CREDIT DESIGNATION STATEMENTS
Live Internet Activity
This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine.

Enduring Material

This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine.

ACCREDITATION STATEMENT

NursingCELogo


Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

DATE OF RELEASE/EXPIRATION
Live Activity
Wednesday, October 21, 2015 from 1:00 PM EST - 2:00 PM EST

Enduring Material

The enduring material will be available from October 21, 2015 – October 21, 2016.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Using data obtained from patients (ie, symptoms, annualized bleeding rate, bleeding phenotype, Hemophilia Joint Health Score), educate patients regarding treatment recommendation for on-demand or prophylactic therapy including its risks and benefits
Identify barriers of adherence and risk factors for low adherence to hemophilia treatment
Monitor treatment outcomes of patients with hemophilia
Design strategies to improve adherence and address side effects
Design a personalized plan to overcome a patient and/or caregiver's barriers to rapid treatment of acute bleeds



TARGET AUDIENCE

This activity is intended for US-based nurses and nurse practitioners involved in the management of patients with hemophilia, including those practicing at recognized hemophilia treatment centers (HTCs).

ESTIMATED TIME TO COMPLETE
This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to http://www.OMedLive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Brenda Riske, RN, MSN, MBA, MPA
Director of Strategic Operations, Hemophilia and Thrombosis Center
University of Colorado

Consulting fees: Bayer HealthCare

Regina B. Butler, RN
Clinical Manager, Hematology
Children’s Hospital of Philadelphia

Consulting fees: Biogen Idec; Pfizer


The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following PlatformQ Health Education, LLC planners, Anne Roc, PhD, and Karen Greb-Murphy hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:
Please contact the Postgraduate Institute of Medicine at www.pimed.com.

Technical Support:
For any technical issues or issues with your CME Certificate, contact NeuroSeriesLive at 877-394-1306 or at Support@OMedLiveLive.com

Invasive Mycoses: A High-Risk Battle in the High-Risk Patient

 

 

 

 


ACKNOWLEDGEMENT

This activity is supported by an educational grant from Astellas.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ Health Education, LLC. Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Tuesday, October 20, 2015 11:00 AM ET – 1:00 PM EST
Enduring Material
The enduring material will be available from October 20, 2015 to April 20, 2016.


LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Promptly evaluate high-risk inpatients with signs or symptoms that are suggestive of systemic fungal infection
Apply the most recent evidence-based guidelines in the management of patients with suspected invasive mycoses
Consider the efficacy and safety of newer azole-based therapies when formulating treatment plans for patients with invasive aspergillosis, candidiasis, or mucormycosis
Compare and contrast the PK/PD characteristics of IV and oral azole formulations and dosing implications for inpatient-to-outpatient management
Assess and monitor patients on concomitant azole therapy and potentially interacting drugs, and modify therapy as indicated to avoid adverse effects

INTENDED AUDIENCE
This activity is intended for oncologists, transplant specialists, infectious disease specialists, surgeons, hospitalists, critical care specialists, microbiologists, pharmacists, nurse practitioners, physician assistants, nurses, and other clinicians involved with the diagnosis and treatment of patients with invasive fungal infections.

ESTIMATED TIME TO COMPLETE
The activity consists of two sessions, each of which should take approximately 1.0 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post- test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Thomas Patterson, MD

Consultant: Astellas, Cidara, Gilead, Merck, Pfizer, Revolution Medicines, Scynexis, Toyama, Viamet, Vical

Research Grants to the UTHSCSA: Astellas, Revolution Medicines .

Nathan P. Wiederhold, PharmD, FCCP

Consultant: Astellas, Merck

Non-CME Service: Astellas

Research: Astellas, bioMerieux, Merck

Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA

Consultant: Merck, Cidara, F2G

Speakers Bureau: Merck

Non-CME Service: Merck

Gilead Research: Astellas

George R. Thompson, MD

Consultant: Astellas

Research: Astellas, Merck

Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University have no disclosures to report relative to this activity.
Ira Leviton, MD Has nothing to disclose relevant to this activity.
PlatformQ Health, Inc  
Carolyn Skowronski, Medical Director Stock Ownership: Merck
Randi O'Hara, Senior Program Manager Has nothing to disclose relevant to this activity.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Advances and Ambitions in the Management of Metastatic Pancreatic Cancer

 

 

 

 


ACKNOWLEDGEMENT

This activity is supported by educational grants from Incyte Corporation and Merrimack Pharmaceuticals.

TUITION
Complimentary

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and PlatformQ Health Education.

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Friday, December 11, 2015 from 10:00 AM EST - 12:00 PM EST

Enduring Material

The enduring material will be available from December 11, 2015 to June 11, 2016.

ACTIVITY DESCRIPTION
Pancreatic cancer is the 4th leading cause of death from cancers in the US, and remains one of the most lethal cancers. Prognosis is poor for 80-85% of patients owing to heterogeneity and aggressive nature of the disease, old age, late diagnosis and late initiation of treatment, sub- optimal drug delivery, treatment toxicity, development of drug resistance, and limited efficacy of systemic treatments. Therapeutic approaches should be individualized due to patient and treatment related issues, but optimizing treatment for individual patients with metastatic pancreatic cancer is an ongoing challenging. Furthermore, treatment strategies are evolving and understanding the practical application of recent advances from clinical studies can be overwhelming. This program aims to improve clinician confidence in their ability to provide timely and accurate care to patients with metastatic pancreatic cancer through discussions on treatment guidelines, combination therapy options, anticipating and recognizing treatment-related toxicities, mechanisms of treatment resistance, and treatment modification to improve patient outcomes.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Determine sequence and timing of initial and subsequent strategies with single agents and in the adjuvant setting to maximize treatment response in patients with MPC
Address chemotherapy induced toxicities and provide supportive care options for patients undergoing treatment for MPC
Describe the mechanisms of chemotherapy resistance in pancreatic tumors
Summarize emerging treatment options, biomarkers, and imaging techniques in clinical development for recurrent and refractory pancreatic cancer

INTENDED AUDIENCE
This activity is intended for medical oncologists, oncology nurses, and other health care professionals involved in the diagnosis and treatment of pancreatic cancer.

ESTIMATED TIME TO COMPLETE
The activity consists of two sessions, each of which should take approximately 1.0 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to http://www.omedlive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post- test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FINANCIAL DISCLOSURES

Presenters: Disclosures:
Eileen O’Reilly, MD

Research grants: Abbott Laboratories, Amgen, Bayer, CASI, Celgene, Eli Lilly and Company/Imclone, Exelixis, Genentech, Immunomedics, Incyte, Momenta Pharmaceuticals, Myriad Genetics, Novartis, OncoMed Pharmaceuticals, Polaris Pharmaceuticals, Roche, and Vicus Therapeutics
Consulting: Aduro Biotech, Array, Astellas Pharma US, BioAlliance, Boston Scientific, Boston Therapeutics, BMS, CASI, Celgene, Cipla, Eli Lilly and Company, EMD Sorono, Gilead, IntegraGen, Medergy, MedImmune, Merrimack, Momenta, Novartis, Onxeo, Pharmacyclics, Sanofi-aventis, Silenseed, Sillajen, and Vicus Therapeutics.

 

 

Tanios Bekaii-Saab, MD

Consulting: Merrimack, Merck KGaA

 

 

University of Nebraska Medical Center, Center for Continuing Education  
Lois Colburn, Executive Director Has nothing to disclose.
Brenda C. Ram, CMP, CHCP, Coordinator Has nothing to disclose.
PlatformQ Health, Inc  
Anne Roc, PhD, Medical Director Has nothing to disclose.
Karen Greb-Murphy, Program Manager Has nothing to disclose.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
The University of Nebraska Medical Center, Center for Continuing Education requires the presenter(s) to inform the audience when off-label or unapproved uses of drugs or devices are being discussed. Devices or drugs that are still undergoing clinical trials will be identified as such and will not be portrayed as standard, accepted therapy.

DISCLAIMERS (if applicable):
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the University of Nebraska Medical Center, Center for Continuing Education, OMedLive, PlatformQ Health or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA- approved uses and any off-label uses.

CONTACT INFORMATION
Accreditation Support:
Please contact the University of Nebraska Medical Center, Center for Continuing Education at conted@unmc.edu or call 402-559-4152.

Techincal Support:
For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Metastatic Colorectal Cancer: An Evolving Diagnostic and Treatment Landscape

 

 

 

 


ACKNOWLEDGEMENT

This activity is supported by educational grants from Genentech, Inc. and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

TUITION
Complimentary

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and PlatformQ Health Education.

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Wednesday, December 16, 2015 from 10:00 AM EST - 12:00 PM EST

Enduring Material

The enduring material will be available from December 16, 2015 – June 16, 2016.

ACTIVITY DESCRIPTION
Despite improved screening rates for colorectal cancer (CRC), deaths from CRC remain unacceptably high, particularly in the metastatic setting and among older and underserved populations. These deaths are preventable with expanded use of effective treatments that can now be individualized to optimally treat specific tumor presentations. Mutation testing can help ensure that patients receive a personalized treatment approach and reduce morbidity and mortality from CRC. These tests, however, need to be better integrated into clinical practice. The challenge faced by physicians is how to select patients based on their tumor mutation status who will benefit the most from specific treatment and the optimal sequencing of therapy. Treatment strategies should also be tailored to patient health status rather than chronological age. Despite the availability of guidelines, adherence to evidence-based recommendations declines significantly when treating older patients; age is often cited as the primary reason for withholding treatment. This program aims to increase physician confidence and knowledge on performing genetic testing and applying the results to treatment selection and patient care. It also aims to increase understanding on clinical trials, as well as strategies to expand access to trials and facilitate communication about participation for those with limited treatment options.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Apply evidence-based recommendations to overcome barriers and improve identification of subtypes and tumor mutations in CRC
Use results from mutation analysis to select treatment for patients with mCRC
Individualize treatment of mCRC, based on tumor profile, biomarker analysis, and patient characteristics
Integrate the safety and efficacy data of novel agents to improve the management and outcomes of patients with mCRC

INTENDED AUDIENCE
This activity is intended for medical oncologists, oncology nurses, gastroenterologists, pathologists, and other health care professionals involved in the diagnosis and treatment of colorectal cancer.

ESTIMATED TIME TO COMPLETE
The activity consists of two sessions, each of which should take approximately 1.0 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to http://www.omedlive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post- test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FINANCIAL DISCLOSURES

Presenters: Disclosures:
Bert H. O’Neil, MD

Consultant: Amgen; Taiho; Roche Genentech

 

 

Andrea Cercek, MD

Dr. Cerek has no financial relationships with a commercial interest/interests producing health care related products and/or services to disclose.

 

 

Wasif M. Saif, MD

Grant funding: Genentech; Celgene; Taiho
Speaker: Sanofi; Ipsen; Novartis; Genentech; Celgene; Sirtex

 

 

University of Nebraska Medical Center, Center for Continuing Education  
Lois Colburn, Executive Director Has nothing to disclose.
Brenda C. Ram, CMP, CHCP, Coordinator Has nothing to disclose.
PlatformQ Health, Inc  
Anne Roc, PhD, Medical Director Has nothing to disclose.
Karen Greb-Murphy, Program Manager Has nothing to disclose.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
The University of Nebraska Medical Center, Center for Continuing Education requires the presenter(s) to inform the audience when off-label or unapproved uses of drugs or devices are being discussed. Devices or drugs that are still undergoing clinical trials will be identified as such and will not be portrayed as standard, accepted therapy.

DISCLAIMERS (if applicable):
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the University of Nebraska Medical Center, Center for Continuing Education, OMedLive, PlatformQ Health or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA- approved uses and any off-label uses.

CONTACT INFORMATION
Accreditation Support:
Please contact the University of Nebraska Medical Center, Center for Continuing Education at conted@unmc.edu or call 402-559-4152.

Techincal Support:
For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Evolving Practices in Chronic Lymphocytic Leukemia

 

 

 

 


ACKNOWLEDGEMENT

This activity is supported by educational grants from Infinity Pharmaceuticals, Inc., and Pharmacyclics, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

TUITION
Complimentary

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and PlatformQ Health Education.

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Physician Assistants may receive a maximum of 1.0 hours of credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Wednesday, January 27, 2016, from 10:00 AM EST - 12:00 PM EST

Enduring Material

The enduring material will be available from January 27, 2016 – July 27, 2016.

ACTIVITY DESCRIPTION
Among adult leukemias, chronic lymphocytic leukemia is the most prevalent, and is associated with the longest lifespan. It is estimated that 15,700 individuals are diagnosed with CLL annually in the United States, approximately 70% of whom will be over the age of 65. Over recent decades, significant advances in the understanding of underlying CLL biology have expanded diagnostic, prognostic, and treatment options, resulting in steadily increasing 5-year relative survival rates for these patients. However, this has been achieved through an increasingly complex treatment paradigm. Today, treatment choice is determined by age, functional status, and specific genomic features. For example, recently updated treatment guidelines include newly approved treatments, and emphasize genetic considerations. Recent advances in both prognostic indicators and biologic therapies challenge clinicians to individualize CLL treatment based on a growing number of disease and patient characteristics. However, busy physicians are challenged to remain current on the latest CLL research and data on new and emerging agents. Improved understanding of disease prognostic factors as well as the efficacy and safety data of new and emerging agents will allow clinicians to integrate these agents effectively into appropriate treatment regimens. Expert guidance, in tandem with continuing medical education, will be critical in helping physicians navigate the current therapeutic landscape for chronic lymphocytic leukemia, thus improving outcomes for patients with CLL.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Identify prognostic factors and patient-specific clinical criteria for selecting treatment strategies for patients with CLL/SLL
Stratify available treatment regimens for patients with CLL based on disease characteristics, age, performance status, and comorbidities
Assess how emerging agents are relevant to practicing clinicians and how they can be assimilated into clinical practice
Apply the latest clinical trial data to manage challenging patients such as those with relapsed/refractory CLL

INTENDED AUDIENCE
This activity is intended for US-based hematologists, oncologists, internal medicine physicians, family medicine/primary care physicians, and other clinicians who care for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

ESTIMATED TIME TO COMPLETE
The activity consists of two sessions, each of which should take approximately 1.0 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to http://www.omedlive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post- test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FINANCIAL DISCLOSURES

Presenters: Disclosures:
John C. Byrd, MD

Research Support: PCYC; Acerta; Genentech

 

 

Jennifer R. Brown, MD, PhD

Consultant: ProNAi Therapeutics; Sun BioPharma, Inc.; Janssen; Gilead; Pharmacyclics; Infinity; Celgene; Roche/Genentech

 

 

University of Nebraska Medical Center, Center for Continuing Education  
Lois Colburn, Executive Director Has nothing to disclose.
Brenda C. Ram, CMP, CHCP, Coordinator Has nothing to disclose.
Matthew Lunning, DO, CME Reviewer Speaking/Teaching Honorarium: Onyx Pharmaceuticals
Advisory Board: Alexion Pharma International Sarl; Genentech, Inc.; Gilead Sciences, Inc.; Spectrum Pharmaceuticals, Inc.; Juno Therapeutics
Investigator Meetings: TG Therapeutics
Faculty Member: Clinical Care Options
   
PlatformQ Health, Inc  
Anne Roc, PhD, Medical Director Has nothing to disclose.
Karen Greb-Murphy, Program Manager Has nothing to disclose.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
The University of Nebraska Medical Center, Center for Continuing Education requires the presenter(s) to inform the audience when off-label or unapproved uses of drugs or devices are being discussed. Devices or drugs that are still undergoing clinical trials will be identified as such and will not be portrayed as standard, accepted therapy.

DISCLAIMERS (if applicable):
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the University of Nebraska Medical Center, Center for Continuing Education, OMedLive, PlatformQ Health or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA- approved uses and any off-label uses.

CONTACT INFORMATION
Accreditation Support:
Please contact the University of Nebraska Medical Center, Center for Continuing Education at conted@unmc.edu or call 402-559-4152.

Techincal Support:
For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com